Literature DB >> 3252754

Pharmacokinetics of LY163892 in infants and children.

J D Nelson1, S Shelton, H Kusmiesz.   

Abstract

Two dosages (7.5 and 15 mg/kg of body weight) of LY163892 were given to infants and children, and five plasma specimens were collected for antibiotic assay during the ensuing 4 h. Peak concentrations of 12.6 and 18.7 micrograms/ml occurred at 45 min. The mean half-lives were 0.85 and 0.78 h, and the mean areas under the curve were 24.4 and 38.0 micrograms.h/ml.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3252754      PMCID: PMC175962          DOI: 10.1128/AAC.32.11.1738

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  Beta-lactamase hydrolysis and inhibition studies of the new 1-carbacephem LY163892.

Authors:  R N Jones; A L Barry
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

2.  In vitro susceptibilities of common pediatric pathogens to LY163892.

Authors:  S Shelton; J D Nelson
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

3.  In vitro activities of LY163892, cefaclor, and cefuroxime.

Authors:  C C Knapp; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

4.  Pharmacokinetics of cefaclor in infants and children.

Authors:  G H McCracken; C M Ginsburg; J C Clahsen; M L Thomas
Journal:  J Antimicrob Chemother       Date:  1978-11       Impact factor: 5.790

  4 in total
  6 in total

1.  Pharmacokinetics of loracarbef in pediatric patients.

Authors:  M C Nahata; K I Koranyi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jul-Sep       Impact factor: 2.441

2.  Loracarbef concentrations in middle ear fluid.

Authors:  H Kusmiesz; S Shelton; O Brown; S Manning; J D Nelson
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

3.  Loracarbef versus cefaclor in the treatment of urinary tract infections in women.

Authors:  A Iravani
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

4.  Bactericidal titers of loracarbef (LY 163892) in serum and killing rates in volunteers receiving 400 versus 200 milligrams.

Authors:  P Van der Auwera
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

Review 5.  Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D McTavish
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

6.  Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media.

Authors:  V N Gan; H Kusmiesz; S Shelton; J D Nelson
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.